Tradestie Institutional Equity Comparison Engine · Market Close Nov 16, 2026

DXR vs AMS: Which Stock Is the Better Buy Now?

Deterministic 6-pillar institutional evaluation across valuation multiples, TTM & multi-year operating margins, cash generation, options IV skew, and supply-chain moat.

DXR Captures Overall Composite Edge (52.2 HOLD vs 33.8 SELL), While AMS Leads 3–2 on Growth & Valuation Pillars

DXR Overall Winner 6-Pillar Tally: DXR 2 – 3 AMS (1 Tie) Matrix Metrics: DXR 7 – 3 AMS

As of Nov 16, 2026, Daxor Corporation (DXR) captures the overall head-to-head institutional edge over American Shared Hospital Services (AMS) on higher Unified Composite conviction (52.2/100 HOLD vs. 33.8/100 SELL) after splitting the core matrix 7–3 (led by Growth & Scale, Profitability & Quality), while AMS wins 3–2 across the 6-pillar growth and valuation breakdown. DXR trades at $8.36 (64.5x Forward P/E, -5894.3% operating margin) versus AMS at $1.07 (44.6x Forward P/E, -7.4% operating margin).

  • Growth vs. Quality Trade-Off: DXR earns the overall head-to-head edge with a stronger Unified Composite Score (52.2/100 HOLD vs. AMS 33.8/100 SELL) and 0.28β · 32% Vol risk profile, whereas AMS leads top-line expansion (+19.2% YoY revenue growth, N/M PEG, and 3 of 6 institutional pillars) for higher-beta growth mandates.
  • Technical & Structure Timing Caution: DXR is currently in a short-term Weinstein Markdown pullback below its falling 50-day moving average (RSI 31.2); meanwhile AMS is in a short-term Weinstein Markdown pullback below its falling 50-day moving average (RSI 27.1). Short-term Markdown, Distribution, or Breakdown phases signal active supply overhead rather than bullish technical support — disciplined entries typically wait for price to reclaim the 20/50-day moving average.

Executive Snapshot Side-by-Side Composite Ratings & Technical Regime

Ask Alpha AI About DXR vs AMS
DXR NASDAQ Head-to-Head Winner
Daxor Corporation Common Stock
Surgical & Medical Instruments & Apparatus
$8.36
-1.47% 1D
Market Cap $49.5M
TTM Revenue $31,360
Forward P/E 64.5x
Beta / 30D Vol 0.28β · 32% Vol
Unified Composite Score
52.2 / 100 HOLD
Tech 52.0 Fund 59.0 Flow 50.0 Mom 64.0
Weinstein Technical Phase Markdown · Sell / avoid
Price below a falling SMA50 (slope -5.2%), weak momentum, RSI 31
RSI-14: 31.2 · SMA20: $8.91 · SMA50: $10.07
AMS NYSE American
American Shared Hospital Services
Services-Medical Laboratories
$1.07
-0.93% 1D
Market Cap $7.2M
TTM Revenue $30M
Forward P/E 44.6x
Beta / 30D Vol 0.18β · 46% Vol
Unified Composite Score
33.8 / 100 SELL
Tech 24.0 Fund 38.0 Flow 50.0 Mom 30.0
Weinstein Technical Phase Markdown · Sell / avoid
Price below a falling SMA50 (slope -7.9%), weak momentum, RSI 27
RSI-14: 27.1 · SMA20: $1.21 · SMA50: $1.32

6-Pillar Scorecard Institutional Category Breakdown (DXR 2 – 3 AMS)

Columns: Metric · DXR · AMS
1. Valuation Multiples AMS
Forward P/E 64.5x 44.6x
Trailing P/E 7.7x 44.6x
PEG Ratio N/M N/M
EV / Revenue N/M 0.8x
2. Growth & Scale DXR
Revenue Growth (YoY) +25.5% +19.2%
Earnings Growth (YoY) +329.3% -38.1%
TTM Revenue (USD) $31,360 $30M
Market Cap $49.5M $7.2M
3. Profitability & Quality DXR
Gross Margin 100.0% 34.8%
Operating Margin -5894.3% -7.4%
Net Profit Margin 19861.4% -5.8%
Return on Equity (ROE) 14.2% -12.1%
4. Balance Sheet & Cash Flow AMS
Cash Generation (TTM) N/A -$916,000
Cash Flow Margin N/A -3.0%
Net Cash / Leverage $8.88 Book/Sh · 14.2% ROE $17M Net Debt (0.95x D/E)
Dividend Yield None (0.00%) None (0.00%)
5. Options & Positioning Tie
Options Structure Phase UNCLASSIFIED UNCLASSIFIED
Current IV / %ile N/A (N/A) N/A (N/A)
Put/Call OI Skew N/A N/A
OBV Trend / Tech Phase NEUTRAL · Markdown NEUTRAL · Markdown
6. R&D & Supply-Chain Moat AMS
OpEx & R&D Intensity N/A 42.2% of Rev ($13M)
90D R&D Disclosures 0 papers 0 papers
Competitive Moat Cyclical / Execution-Driven Positioning Cyclical / Execution-Driven Positioning
Supply-Chain Role Medical Instruments & Supplies Operator Medical Care Facilities Operator

Core Matrix Head-to-Head Valuation, Margin, Cash Flow & Risk Table

Core Matrix Wins: DXR (7) vs AMS (3)
Institutional Metric DXR AMS Criterion Row Edge
Market Capitalization
Scale
$49.5M $7.2M Larger Scale DXR
Trailing P/E Ratio
Valuation
7.7x 44.6x Lower Multiple DXR
Forward P/E Ratio
Valuation
64.5x 44.6x Lower Multiple AMS
Revenue Growth (YoY)
Growth
+25.5% +19.2% Higher Growth DXR
Operating Margin (TTM)
Profitability
-5894.3% -7.4% Higher Margin AMS
Net Profit Margin
Profitability
19861.4% -5.8% Higher Margin DXR
Return on Equity (ROE)
Capital Efficiency
14.2% -12.1% Higher ROE DXR
52-Week Range Position
Momentum
2% ($8–$15) 6% ($1–$2) Stronger Trend AMS
Beta / 30D Volatility
Risk Regime
0.28β · 32% Vol 0.18β · 46% Vol Lower Realized Risk DXR
Unified Institutional Score
Composite Signal
52.2 / 100 (HOLD) 33.8 / 100 (SELL) Higher Composite DXR
Trailing 12M Revenue (USD)
Operating Scale
$31,360 $30M FX-Normalized USD Scale
Gross Profit Margin (TTM)
Unit Pricing Power
100.0% 34.8% Higher Margin Quality
PEG Ratio & EV / Revenue
Growth-Adjusted Valuation
N/M PEG · N/M EV/Rev N/M PEG · 0.8x EV/Rev Lower Multiple Valuation
Cash Flow & Balance Sheet
Capital Self-Funding
N/A ($8.88 Book/Sh · 14.2% ROE) -$916,000 ($17M Net Debt (0.95x D/E)) Higher Cash / Net Cash Solvency

Momentum Normalized Relative Price Performance (1M · 3M · 6M · 1Y)

1M Horizon AMS +0.46 pp
DXR: -16.87% · AMS: -16.41%
3M Horizon DXR +13.47 pp
DXR: -19.66% · AMS: -33.13%
6M Horizon DXR +24.41 pp
DXR: -17.44% · AMS: -41.85%
1Y Horizon DXR +18.96 pp
DXR: -33.27% · AMS: -52.23%

Financial Trajectory Operating Profitability Benchmark (Trailing 12-Month)

Split-Invariant USD Revenue & Operating Margin (%)

Standardized multi-year USD domestic revenue schedules are unavailable for foreign-domiciled ADR filing schedules on DXR vs AMS. Trailing 12-month operating profitability (DXR -5894.3% vs AMS -7.4%) and valuation multiples (DXR 64.5x vs AMS 44.6x Forward P/E) are benchmarked directly in Pillar 4 below.

DXR ADR TTM Benchmark FX-Normalized USD
TTM Revenue$31,360
Gross Margin100.0%
Op. Margin-5894.3%
ROE / Fwd P/E14.2% · 64.5x
AMS ADR TTM Benchmark FX-Normalized USD
TTM Revenue$30M
Gross Margin34.8%
Op. Margin-7.4%
ROE / Fwd P/E-12.1% · 44.6x

Options Positioning Implied Volatility, Put/Call Skew & Dealer Gamma Corridor

Live Options Phase Tracker
DXR UNCLASSIFIED
0d in phase · OBV NEUTRAL
Current IV N/A
IV Percentile N/A
Put/Call OI Skew N/A
IV Regime Unclassified
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
Net Delta Signal NEUTRAL
OBV Flow NEUTRAL
Exact DXR Put/Call Gamma Wall strikes & dealer pinning corridor require Tradestie Pro. Unlock 14-Day Free Trial →
AMS UNCLASSIFIED
0d in phase · OBV NEUTRAL
Current IV N/A
IV Percentile N/A
Put/Call OI Skew N/A
IV Regime Unclassified
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
Net Delta Signal NEUTRAL
OBV Flow NEUTRAL
Exact AMS Put/Call Gamma Wall strikes & dealer pinning corridor require Tradestie Pro. Unlock 14-Day Free Trial →

Moat & R&D Supply-Chain Positioning, Bottleneck Moat & R&D Velocity

Corporate R&D & Foundry Leaderboard
DXR Moat Profile Cyclical / Execution-Driven Positioning
Medical Instruments & Supplies Operator
Competes within the Medical Instruments & Supplies value chain with $49.5M market capitalization and -5894.3% operating margin.
OpEx & R&D Reinvestment N/A
90D Engineering Disclosures 0 Published
AMS Moat Profile Cyclical / Execution-Driven Positioning
Medical Care Facilities Operator
Competes within the Medical Care Facilities value chain with $7.2M market capitalization and -7.4% operating margin.
OpEx & R&D Reinvestment 42.2% of Rev ($13M)
90D Engineering Disclosures 0 Published
Mapped Supply-Chain Ecosystem (18 partners):
Taiwan Semiconductor Manufacturing Company GlobalFoundries ASE Technology Holding Amkor Technology

Investor FAQ DXR vs AMS Key Questions & Quantitative Answers

As of Nov 16, 2026, Daxor Corporation (DXR) captures the overall head-to-head institutional edge over American Shared Hospital Services (AMS) on higher Unified Composite conviction (52.2/100 HOLD vs. 33.8/100 SELL) after splitting the core matrix 7–3 (led by Growth & Scale, Profitability & Quality), while AMS wins 3–2 across the 6-pillar growth and valuation breakdown. DXR trades at $8.36 (64.5x Forward P/E, -5894.3% operating margin) versus AMS at $1.07 (44.6x Forward P/E, -7.4% operating margin). Growth vs. Quality Trade-Off: DXR earns the overall head-to-head edge with a stronger Unified Composite Score (52.2/100 HOLD vs. AMS 33.8/100 SELL) and 0.28β · 32% Vol risk profile, whereas AMS leads top-line expansion (+19.2% YoY revenue growth, N/M PEG, and 3 of 6 institutional pillars) for higher-beta growth mandates. Technical & Structure Timing Caution: DXR is currently in a short-term Weinstein Markdown pullback below its falling 50-day moving average (RSI 31.2); meanwhile AMS is in a short-term Weinstein Markdown pullback below its falling 50-day moving average (RSI 27.1). Short-term Markdown, Distribution, or Breakdown phases signal active supply overhead rather than bullish technical support — disciplined entries typically wait for price to reclaim the 20/50-day moving average.

DXR leads the Growth & Scale pillar: DXR posts +25.5% YoY revenue growth and +329.3% YoY earnings growth on $31,360 TTM revenue (100.0% gross margin, -5894.3% operating margin), compared with AMS at +19.2% YoY revenue growth and -38.1% YoY earnings growth on $30M TTM revenue (34.8% gross margin, -7.4% operating margin). On trailing 12-month operating scale, DXR generates $31,360 in USD-normalized revenue versus $30M for AMS. In operating R&D and SG&A reinvestment, DXR deploys N/A (0 90-day corporate R&D disclosures) versus 42.2% of Rev ($13M) (0 disclosures) for AMS.

AMS screens cheaper on headline valuation multiples. DXR trades at 64.5x Forward P/E, 7.7x Trailing P/E, N/M PEG, and N/M EV/Revenue (unreported cash flow margin), whereas AMS trades at 44.6x Forward P/E, 44.6x Trailing P/E, N/M PEG, and 0.8x EV/Revenue (-3.0% FCF margin). Multiples above 150x or negative earnings denominators are marked N/M to avoid distorted accounting comparisons; weigh lower Forward P/E and PEG against DXR (14.2% ROE) versus AMS (-12.1% ROE) capital efficiency.

In options market volatility and institutional positioning, DXR carries N/A implied volatility (N/A, Unclassified), unclassified Put/Call open interest, NEUTRAL on-balance volume, and sits in an UNCLASSIFIED options structure phase (0.28β · 32% Vol realized risk). By comparison, AMS carries N/A implied volatility (N/A, Unclassified), unclassified Put/Call open interest, NEUTRAL on-balance volume, and sits in an UNCLASSIFIED options structure phase (0.18β · 46% Vol realized risk).

Cross-Compare 1-Click Peer Rivalries & Single-Stock Research

Launch Custom Ticker Comparison →

Powered by Tradestie Institutional Equity Comparison Engine & standardized corporate financial telemetry. Market close as of Nov 16, 2026. For educational research only; not investment advice.